Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience

Objective: Redditux® (RED), as a biosimilar rituximab, was approved in Turkey for all indications of the original Mabthera® (MAB) in March 2018. The aim of our study was to evaluate the efficacy and safety of RED in de novo diffuse large B-cell lymphoma. Materials and Methods: Fifty-one patients rec...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Murat Özbalak, Metban Mastanzade, Dilek Özden Özlük, Tarık Onur Tiryaki, Simge Erdem, Ezgi Pınar Özbalak, Tuğrul Elverdi, İpek Yçnal Hindilerden, Ali Yılmaz Altay, Gülçin Yeğen, Ahmet Emre Eşkazan, Muhlis Cem Ar, Mustafa Nuri Yenerel, Teoman Soysal, Meliha Nalçacı, Burhan Ferhanoğlu, Sevgi Kalayoğlu Beşışık
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Turkish Society of Hematology 2022-11-01
Serie:	Turkish Journal of Hematology
Soggetti:	rituximab biosimilar redditux diffuse large b-cell lymphoma non-hodgkin lymphoma
Accesso online:	https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-27443
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!